[go: up one dir, main page]

DE60040274D1 - Verabreichung von nukleinsäuren und proteinen an zellen - Google Patents

Verabreichung von nukleinsäuren und proteinen an zellen

Info

Publication number
DE60040274D1
DE60040274D1 DE60040274T DE60040274T DE60040274D1 DE 60040274 D1 DE60040274 D1 DE 60040274D1 DE 60040274 T DE60040274 T DE 60040274T DE 60040274 T DE60040274 T DE 60040274T DE 60040274 D1 DE60040274 D1 DE 60040274D1
Authority
DE
Germany
Prior art keywords
proteins
cells
nucleic acids
administration
polynucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60040274T
Other languages
English (en)
Inventor
Peter Francis Joseph O'hare
Nadia Michelle Normand
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Marie Curie Cancer Care
Original Assignee
Phogen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9905444.7A external-priority patent/GB9905444D0/en
Priority claimed from GBGB9930499.0A external-priority patent/GB9930499D0/en
Application filed by Phogen Ltd filed Critical Phogen Ltd
Application granted granted Critical
Publication of DE60040274D1 publication Critical patent/DE60040274D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
DE60040274T 1999-03-10 2000-03-10 Verabreichung von nukleinsäuren und proteinen an zellen Expired - Fee Related DE60040274D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9905444.7A GB9905444D0 (en) 1999-03-10 1999-03-10 Delivery of sustances to cells
GBGB9930499.0A GB9930499D0 (en) 1999-12-24 1999-12-24 Delivery of substances to cells
PCT/GB2000/000897 WO2000053722A2 (en) 1999-03-10 2000-03-10 Delivery of nucleic acids and proteins to cells

Publications (1)

Publication Number Publication Date
DE60040274D1 true DE60040274D1 (de) 2008-10-30

Family

ID=26315249

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60040274T Expired - Fee Related DE60040274D1 (de) 1999-03-10 2000-03-10 Verabreichung von nukleinsäuren und proteinen an zellen

Country Status (9)

Country Link
US (1) US20040171044A1 (de)
EP (1) EP1159441B8 (de)
JP (1) JP2002537828A (de)
AT (1) ATE408699T1 (de)
AU (1) AU767195B2 (de)
CA (1) CA2365625A1 (de)
DE (1) DE60040274D1 (de)
MX (1) MXPA01009073A (de)
WO (1) WO2000053722A2 (de)

Families Citing this family (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393529B2 (en) 1998-04-09 2008-07-01 Idexx Laboratories, Inc. Methods and compositions for inhibiting binding of IgE to a high affinity receptor
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
GB0022101D0 (en) * 2000-09-08 2000-10-25 Phogen Ltd Delivery of substances to cells
ES2383516T3 (es) 2000-11-29 2012-06-21 Pci Biotech As Internalización fotoquímica para suministrar moléculas en el citosol
CN100490902C (zh) 2000-11-29 2009-05-27 Pci生物技术联合股份有限公司 病毒介导的分子传递进入胞质溶胶的光化学内在化
US7517864B2 (en) 2001-05-18 2009-04-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050148530A1 (en) 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
EP1432724A4 (de) 2002-02-20 2006-02-01 Sirna Therapeutics Inc Durch rna-interferenz vermittelte inhibierung von map-kinase-genen
US7923547B2 (en) 2002-09-05 2011-04-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
WO2005019249A2 (en) 2003-08-15 2005-03-03 University Of Florida Identification of porphyromonas gingivalis virulence polynucleotides for diagnosis, treatment, and monitoring of periodontal diseases
GB0321311D0 (en) * 2003-09-12 2003-10-15 Phogen Ltd Delivery of substances to cells
CN102321584B (zh) 2003-12-31 2014-01-08 宾夕法尼亚州研究基金会 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法
WO2005097993A2 (en) * 2004-02-19 2005-10-20 Coley Pharmaceutical Group, Inc. Immunostimulatory viral rna oligonucleotides
ES2423060T3 (es) 2004-03-12 2013-09-17 Alnylam Pharmaceuticals, Inc. Agentes iRNA que tienen como diana al VEGF
US20060040882A1 (en) 2004-05-04 2006-02-23 Lishan Chen Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
WO2006009575A1 (en) 2004-06-22 2006-01-26 The Board Of Trustees Of The University Of Illinois METHODS OF INHIBITING TUMOR CELL PROLIFERATION WITH FOXM1 siRNA
US7737265B2 (en) 2005-06-27 2010-06-15 Alnylam Pharmaceuticals, Inc. RNAi modulation of HIF-1 and therapeutic uses thereof
US20070213292A1 (en) 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
ES2539830T3 (es) 2006-01-20 2015-07-06 Cell Signaling Technology, Inc. ROS quinasa mutante y de translocación en el carcinoma pulmonar no microcítico humano
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
WO2007109097A2 (en) 2006-03-16 2007-09-27 Alnylam Pharmaceuticals, Inc. RNAi MODULATION OF TGF-BETA AND THERAPEUTIC USES THEREOF
JP5704741B2 (ja) 2006-03-31 2015-04-22 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｅｇ５遺伝子発現の抑制のための組成物および方法
ES2561406T3 (es) 2006-04-14 2016-02-26 Cell Signaling Technology, Inc. Defectos de genes y quinasa ALK mutante en tumores sólidos humanos
US8377448B2 (en) 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
WO2008009477A2 (en) 2006-07-21 2008-01-24 Silence Therapeutics Ag Means for inhibiting the expression of protein kinase 3
JPWO2008015841A1 (ja) * 2006-08-02 2009-12-17 梅澤　喜夫 キナーゼ阻害性融合タンパク質と医薬組成物
AU2007292219B2 (en) 2006-09-06 2014-04-24 The Regents Of The University Of California Molecular diagnosis and classification of malignant melanoma
EP2444410A3 (de) 2007-02-28 2012-08-08 The Govt. Of U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services Brachyurie-Polypeptide und Verwendungsverfahren
EP2494993B1 (de) 2007-05-04 2018-08-01 Marina Biotech, Inc. Aminosäure-Lipide und ihre Verwendungen
AR066984A1 (es) 2007-06-15 2009-09-23 Novartis Ag Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)
WO2009021708A2 (en) 2007-08-13 2009-02-19 Baxter International Inc. Ivig modulation of chemokines for treatment of multiple sclerosis, alzheimer's disease, and parkinson's disease
DK2203558T3 (en) 2007-10-18 2016-06-27 Cell Signaling Technology Inc TRANSLOCATION AND mutant ROS kinase IN HUMAN NON-small cell lung carcinoma
US8609347B2 (en) 2007-10-22 2013-12-17 The Regents Of The University Of California Biomarkers for prenatal diagnosis of congenital cytomegalovirus
ES2424329T3 (es) 2008-03-05 2013-10-01 The Regents Of The University Of California Diagnóstico molecular y clasificación de melanoma maligno
US8703921B2 (en) * 2008-04-15 2014-04-22 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Compositions and methods for delivering inhibitory oligonucleotides
US10485879B2 (en) 2008-04-15 2019-11-26 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Plasma cell cytokine vehicle containing fusion proteins for targeted introduction of siRNA into cells and tissues
WO2009140679A2 (en) 2008-05-16 2009-11-19 The Children's Hospital Of Philadelphia Genetic alterations on chromosomes 21q, 6q and 15q and methods of use thereof for the diagnosis and treatment of type i diabetes
ATE550024T1 (de) 2008-05-30 2012-04-15 Univ Yale Gezielte oligonucleotid-zusammensetzungen zur modifizierung der genexpression
CA2726052A1 (en) 2008-06-04 2009-12-10 The Board Of Regents Of The University Of Texas System Modulation of gene expression through endogenous small rna targeting of gene promoters
EP2165710A1 (de) 2008-09-19 2010-03-24 Institut Curie Tyrosinkinaserezeptor Tyro3 als therapeutisches Target bei der Behandlung eines Blasentumors
US20100112042A1 (en) 2008-10-16 2010-05-06 Mdrna, Inc. Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics
KR101785118B1 (ko) 2008-10-27 2017-10-12 박스알타 인코퍼레이티드 혈전성 혈소판감소성 자반증의 모델 및 그의 이용 방법
EP2198879A1 (de) 2008-12-11 2010-06-23 Institut Curie CD74-modulierender Wirkstoff zur Regulierung der Dendritenzellmigration und Verfahren zur Untersuchung der Bewegungsfähigkeit einer Zelle
HUE035769T2 (en) 2009-02-12 2018-05-28 Cell Signaling Technology Inc Mutant ROS expression in human liver cancer
WO2010091878A2 (en) 2009-02-13 2010-08-19 Silence Therapeutics Ag Means for inhibiting the expression of opa1
JP2012517815A (ja) 2009-02-18 2012-08-09 サイレンス・セラピューティクス・アーゲー Ａｎｇ２の発現を阻害するための手段
EP2408458A1 (de) 2009-03-19 2012-01-25 Merck Sharp&Dohme Corp. Rna-schnittstellen-vermittelte unterdrückung der signal transducer and activator of transcription 6 (stat6) genexpression mit short interfering nucleic acid (sina)
EP2408916A2 (de) 2009-03-19 2012-01-25 Merck Sharp&Dohme Corp. Rna-interferenz-vermittelte hemmung der genexpression von ctgf (connective tissue growth factor) unter verwendung von sina (short interfering nucleic acid)
EP2408915A2 (de) 2009-03-19 2012-01-25 Merck Sharp&Dohme Corp. Rna-interferenz-vermittelte hemmung der genexpression von gata-bindungsprotein 3 (gata3) unter verwendung von sina (short interfering nucleic acid)
JP2012520684A (ja) 2009-03-19 2012-09-10 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたＢＴＢａｎｄＣＮＣＨｏｍｏｌｏｇｙ１（塩基性ロイシンジッパー転写因子１）（Ｂａｃｈ１）遺伝子発現のＲＮＡ干渉媒介性阻害
EP2411520A2 (de) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. Rna-interferenz-vermittelte hemmung der genexpression von tslp (thymic stromal lymphopoietin) unter verwendung von sina (short interfering nucleic acid)
KR20110138223A (ko) 2009-03-27 2011-12-26 머크 샤프 앤드 돔 코포레이션 짧은 간섭 핵산 (ｓｉＮＡ)을 사용한 세포간 부착 분자 1 (ＩＣＡＭ-1) 유전자 발현의 ＲＮＡ 간섭 매개 억제
US20120004281A1 (en) 2009-03-27 2012-01-05 Merck Sharp & Dohme Corp RNA Interference Mediated Inhibition of the Nerve Growth Factor Beta Chain (NGFB) Gene Expression Using Short Interfering Nucleic Acid (siNA)
EP2411019A2 (de) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. Rna-interferenz-vermittelte hemmung der signal transducer and activator of transcription 1 (stat1) gen-expression mittels sina (short interfering nucleic acid)
JP2012521760A (ja) 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたアポトーシスシグナル調節キナーゼ１（ＡＳＫ１）遺伝子発現のＲＮＡ干渉媒介性阻害
PT2417257E (pt) 2009-04-10 2016-06-03 Universität Bern Oligonucleótidos triciclo-dna anti-sentido, composições, e métodos para o tratamento de doença
EP2421972A2 (de) 2009-04-24 2012-02-29 The Board of Regents of The University of Texas System Modulation der genexpression mit auf genregionen nach 3-untranslatierten regionen gerichteten oligomeren
EP2266550A1 (de) 2009-06-15 2010-12-29 Institut Curie Antagonisten von ß-Catenin zur Prävention und/oder Behandlung neurodegenerativer Erkrankungen
WO2011072082A2 (en) 2009-12-09 2011-06-16 Nitto Denko Corporation Modulation of hsp47 expression
US9597346B2 (en) 2010-01-15 2017-03-21 Cornell University Methods for reducing protein levels in a cell
WO2011094759A2 (en) 2010-02-01 2011-08-04 The Regents Of The University Of California Novel diagnostic and therapeutic targets associated with or regulated by n-cadherin expression and/or epithelial to mesenchymal transition (emt) in prostate cancer and other malignancies
WO2011120023A1 (en) 2010-03-26 2011-09-29 Marina Biotech, Inc. Nucleic acid compounds for inhibiting survivin gene expression uses thereof
WO2011133584A2 (en) 2010-04-19 2011-10-27 Marina Biotech, Inc. Nucleic acid compounds for inhibiting hras gene expression and uses thereof
WO2011139842A2 (en) 2010-04-28 2011-11-10 Marina Biotech, Inc. Nucleic acid compounds for inhibiting fgfr3 gene expression and uses thereof
US9273316B2 (en) 2010-05-21 2016-03-01 Peptimed, Inc. Reagents and methods for treating cancer
WO2011151321A1 (en) 2010-05-31 2011-12-08 Institut Curie Asf1b as a prognosis marker and therapeutic target in human cancer
US9045755B2 (en) 2010-06-24 2015-06-02 Quark Pharmaceuticals, Inc. Double stranded RNA compounds to RhoA and use thereof
CN107090456B (zh) 2010-08-02 2022-01-18 瑟纳治疗公司 使用短干扰核酸的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1基因表达的抑制
AU2011287430A1 (en) 2010-08-04 2013-03-21 Cizzle Biotechnology Limited Methods and compounds for the diagnosis and treatment of cancer
US20120101108A1 (en) 2010-08-06 2012-04-26 Cell Signaling Technology, Inc. Anaplastic Lymphoma Kinase In Kidney Cancer
AU2011292261B2 (en) 2010-08-17 2015-05-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
JP6106085B2 (ja) 2010-08-24 2017-03-29 サーナ・セラピューティクス・インコーポレイテッドＳｉｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 内部非核酸スペーサーを含む一本鎖ＲＮＡｉ剤
US9233997B2 (en) 2010-08-26 2016-01-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of prolyl hydroxylase domain 2 (PHD2) gene expression using short interfering nucleic acid (siNA)
JP2014500707A (ja) 2010-09-27 2014-01-16 ザ チルドレンズ ホスピタル オブ フィラデルフィア 炎症性腸疾患の治療および診断に有用な組成および方法
AU2011308567B2 (en) 2010-10-01 2015-09-03 Fundacion Centro Nacional De Investigaciones Oncologicas, Carlos Iii Manipulation of stem cell function by p53 isoforms
US20140134231A1 (en) 2010-10-11 2014-05-15 Sanford-Burnham Medical Research Institute Mir-211 expression and related pathways in human melanoma
EP3327125B1 (de) 2010-10-29 2020-08-05 Sirna Therapeutics, Inc. Rna-interferenz-vermittelte inhibition von genexpression unter verwendung kurzer interferierender nukleinsäure (sina)
WO2012061443A2 (en) 2010-11-01 2012-05-10 NanoOncology, Inc. Compositions of a peptide-based system for cell-specific targeting
EP2455456A1 (de) 2010-11-22 2012-05-23 Institut Curie Verwendung von Kinesininhibitoren bei der Behandlung von HIV-Infektion und Verfahren zu deren Abtastung
AU2012217723A1 (en) 2011-02-15 2013-08-29 Immune Design Corp. Methods for enhancing immunogen specific immune responses by vectored vaccines
WO2012118910A2 (en) 2011-03-03 2012-09-07 Quark Pharmaceuticals, Inc. Compositions and methods for treating lung disease and injury
JP6054942B2 (ja) 2011-04-08 2016-12-27 イミューン デザイン コーポレイション 免疫原性組成物、ならびに体液性および細胞性免疫応答を誘発するための該組成物の使用方法
WO2012175481A1 (en) 2011-06-20 2012-12-27 Institut Curie Compositions and methods for treating leukemia
EP2557089A2 (de) 2011-07-15 2013-02-13 Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Zusammensetzungen und Verfahren zur Immunmodulation
PT2581448E (pt) 2011-10-13 2015-05-21 Institut National De La Santé Et De La Rech Médicale (Inserm) Dna triciclo-fosforotioato
CN107880101B (zh) 2011-11-11 2021-12-21 弗雷德哈钦森癌症研究中心 针对癌症的靶向细胞周期蛋白a1的t细胞免疫疗法
US20140364484A1 (en) 2012-01-12 2014-12-11 Quark Pharmaceuticals, Inc. Combination therapy for treating hearing and balance disorders
EP2617434A1 (de) 2012-01-20 2013-07-24 Laboratorios Del. Dr. Esteve, S.A. HIV-1-Integrase-defiziente Immunogene und Verfahren zum Beladen von dentritischen Zellen mit besagten Immunogenen
WO2013123996A1 (en) 2012-02-24 2013-08-29 Astrazeneca Uk Limited Novel sirna inhibitors of human icam-1
EP3336181B1 (de) 2012-04-18 2022-01-12 Cell Signaling Technology, Inc. Egfr und ros1 bei krebs
US9932578B2 (en) 2012-09-12 2018-04-03 Quark Pharmaceuticals, Inc. Double-stranded oligonucleotide molecules to P53 and methods of use thereof
ES2704855T3 (es) 2012-09-12 2019-03-20 Quark Pharmaceuticals Inc Moléculas de oligonucleótido de doble cadena para p53 y métodos de uso de las mismas
US9868949B2 (en) 2013-02-28 2018-01-16 Arrowhead Pharmaceuticals, Inc. Organic compositions to treat EPAS1-related diseases
WO2014135655A1 (en) 2013-03-06 2014-09-12 Institut Curie Compositions and methods for treating muscle-invasive bladder cancer
JO3564B1 (ar) 2013-03-08 2020-07-05 Novartis Ag ببتيدات وتركيبات لعلاج ضرر المفاصل
WO2014154898A1 (en) 2013-03-29 2014-10-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) Prognosis and treatment of cancers
WO2015020960A1 (en) 2013-08-09 2015-02-12 Novartis Ag Novel lncrna polynucleotides
EP2853595A1 (de) 2013-09-30 2015-04-01 Soluventis GmbH NOTCH 1-spezifische siRNA-Moleküle
WO2015123496A1 (en) 2014-02-14 2015-08-20 Immune Design Corp. Immunotherapy of cancer through combination of local and systemic immune stimulation
KR102375396B1 (ko) 2014-05-13 2022-03-18 노파르티스 아게 연골형성을 유도하기 위한 화합물 및 조성물
TW201620526A (zh) 2014-06-17 2016-06-16 愛羅海德研究公司 用於抑制α－１抗胰蛋白酶基因表現之組合物及方法
CA2955015A1 (en) 2014-07-15 2016-01-21 Immune Design Corp. Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector
JP2017530948A (ja) 2014-08-27 2017-10-19 ペプティメド， インコーポレイテッド 抗腫瘍組成物および方法
WO2016083624A1 (en) 2014-11-28 2016-06-02 Silence Therapeutics Gmbh Means for inhibiting the expression of edn1
CN113493789A (zh) 2015-03-17 2021-10-12 箭头药业股份有限公司 用于抑制因子xii的基因表达的组合物和方法
WO2016196366A1 (en) 2015-05-29 2016-12-08 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Extension of replicative lifespan in diseases of premature aging using p53 isoforms
EP3302503A4 (de) 2015-05-29 2019-08-07 Arrowhead Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur hemmung der genexpression von hif2alpha
CA2991639A1 (en) 2015-08-07 2017-02-16 Arrowhead Pharmaceuticals, Inc. Rnai therapy for hepatitis b virus infection
JOP20210043A1 (ar) 2015-10-01 2017-06-16 Arrowhead Pharmaceuticals Inc تراكيب وأساليب لتثبيط تعبير جيني للـ lpa
EP3156497A1 (de) 2015-10-16 2017-04-19 Centre National de la Recherche Scientifique (C.N.R.S.) Trpv2 als biomarker und als therapeutisches target für melanome
EP3445385A4 (de) 2016-04-18 2019-11-20 The Trustees of Columbia University in the City of New York An der progression nichtalkoholischer steatohepatitis (nash) beteiligte therapeutische ziele
AU2017279512B2 (en) 2016-06-06 2021-08-19 Arrowhead Pharmaceuticals, Inc. 5'-cyclo-phosphonate modified nucleotides
EP3269734A1 (de) 2016-07-15 2018-01-17 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Verfahren und zusammensetzungen zur behandlung von krebs
JOP20170161A1 (ar) 2016-08-04 2019-01-30 Arrowhead Pharmaceuticals Inc عوامل RNAi للعدوى بفيروس التهاب الكبد ب
TWI826365B (zh) 2017-01-10 2023-12-21 美商愛羅海德製藥公司 α-1抗胰蛋白酶 (AAT) RNAi 藥劑、包含AAT RNAi 藥劑之組合物及使用方法
AU2018297262A1 (en) 2017-07-06 2020-02-27 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of alpha-ENaC and methods of use
EP3449978A1 (de) 2017-09-01 2019-03-06 Universite Paris Descartes Inhibitoren des arylkohlenwasserstoffrezeptors zur behandlung von weichteilsarkom und prävention von neurofibromwachstum und/oder transformation auf malignen peripheren nervenscheidentumoren
EP3681516A4 (de) 2017-09-11 2021-09-29 Arrowhead Pharmaceuticals, Inc. Rnai-mittel und zusammensetzungen zur hemmung der expression von apolipoprotein c-iii (apoc3)
JP7281452B2 (ja) 2017-09-14 2023-05-25 アローヘッド ファーマシューティカルズ インコーポレイテッド アンジオポエチン様３（ＡＮＧＰＴＬ３）の発現を阻害するためのＲＮＡｉ剤および組成物、ならびに使用方法
WO2019068326A1 (en) 2017-10-05 2019-04-11 Université D'aix-Marseille INHIBITORS OF LSD1 FOR THE TREATMENT AND PREVENTION OF CARDIOMYOPATHIES
US11492624B2 (en) 2017-10-17 2022-11-08 Arrowheads Pharmaceuticals, Inc. RNAi agents and compositions for inhibiting expression of Asialoglycoprotein receptor 1
US11021692B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Hepatitis B virus (HBV) vaccines and uses thereof
CN113613661A (zh) 2019-01-09 2021-11-05 箭头药业股份有限公司 用于抑制HIF-2α(EPAS1)的表达的RNAi试剂、其组合物和使用方法
EP3920884A1 (de) 2019-02-07 2021-12-15 Arrowhead Pharmaceuticals, Inc. Rnai-mittel gegen infektion mit dem hepatitis-b-virus
BR112021018506A2 (pt) 2019-03-19 2021-11-30 Fundacio Privada Inst Dinvestigacio Oncològica De Vall Hebron Terapia de combinação para tratamento do câncer
TW202106294A (zh) 2019-04-18 2021-02-16 美商健生醫藥公司 用於治療ｂ型肝炎病毒感染的組合療法（一）
TW202103698A (zh) 2019-04-18 2021-02-01 美商健生醫藥公司 用於治療b型肝炎病毒感染之組合療法
JP2022536945A (ja) 2019-06-18 2022-08-22 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー Ｂ型肝炎ウイルス（ＨＢＶ）ワクチンおよびＨＢＶを標的化するＲＮＡｉの組合せ
EP3986456A1 (de) 2019-06-18 2022-04-27 Janssen Sciences Ireland Unlimited Company Kombination von hepatitis-b-virus(hbv)-impfstoffen und auf hbv abzielender rnai
EP3808763A1 (de) 2019-10-17 2021-04-21 Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Verbindungen zur immunmodulation
EP4114944A1 (de) 2020-03-04 2023-01-11 Ninovax Produkte zur unterdrückung oder verringerung der expression oder aktivität einer snorna und verwendungen davon bei der behandlung von krebs
US20210285000A1 (en) 2020-03-05 2021-09-16 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
WO2021195467A2 (en) 2020-03-26 2021-09-30 Arrowhead Pharmaceuticals, Inc. RNAi AGENTS FOR INHIBITING EXPRESSION OF PNPLA3, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE
TW202207950A (zh) 2020-06-22 2022-03-01 美商詹森藥物公司 治療d型肝炎病毒感染之組合物及方法
TW202227627A (zh) 2020-09-11 2022-07-16 美商愛羅海德製藥公司 用於抑制DUX4表現之RNAi藥劑、其組合物及使用方法
IL301186A (en) 2020-09-11 2023-05-01 Arrowhead Pharmaceuticals Inc Skeletal muscle delivery platforms and methods of use
MX2023002883A (es) 2020-09-11 2023-03-31 Arrowhead Pharmaceuticals Inc Conjugados lipidicos para el transporte de agentes terapeuticos.
TW202245809A (zh) 2020-12-18 2022-12-01 美商詹森藥物公司 用於治療b型肝炎病毒感染之組合療法
WO2022152869A1 (en) 2021-01-15 2022-07-21 Janssen Sciences Ireland Unlimited Company Use of oligonucleotides for individuals with hepatic impairment
US11629349B2 (en) 2021-06-21 2023-04-18 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use
CN117616121A (zh) 2021-07-09 2024-02-27 葛兰素史密斯克莱知识产权(第3号)有限公司 寡核苷酸用于具有肾脏损伤的个体的用途
JP2024540971A (ja) 2021-10-20 2024-11-06 ユニバーシティ オブ ロチェスター 加齢性白質喪失の競合治療における使用のための単離されたグリア前駆細胞
WO2023233290A1 (en) 2022-05-31 2023-12-07 Janssen Sciences Ireland Unlimited Company Rnai agents targeting pd-l1
WO2023245060A2 (en) 2022-06-15 2023-12-21 Arrowhead Pharmaceuticals, Inc. Rnai agents for inhibiting expression of superoxide dismutase 1 (sod1), compositions thereof, and methods of use
WO2024089013A1 (en) 2022-10-25 2024-05-02 Peptomyc, S.L. Combination therapy for the treatment of cancer
WO2024126765A1 (en) 2022-12-16 2024-06-20 Université De Strasbourg Rnai-based therapies targeting claudin-1 for the treatment and prevention of fibrotic diseases
WO2024163747A2 (en) 2023-02-02 2024-08-08 University Of Rochester Competitive replacement of glial cells
EP4410825A1 (de) 2023-02-03 2024-08-07 Servizo Galego de Saude Fragmente der n-terminalen domäne von gsdmb zur behandlung von krebs
WO2024251854A1 (en) 2023-06-07 2024-12-12 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Combination therapy with braf inhibitors for the treatment of cancer
EP4473974A1 (de) 2023-06-07 2024-12-11 Peptomyc, S.L. Omomyc und kras-hemmern kombinationstherapie zur behandlung von krebs
WO2024251846A1 (en) 2023-06-07 2024-12-12 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Combination therapy with mek inhibitors for the treatment of cancer
WO2025072748A2 (en) 2023-09-29 2025-04-03 Insitro, Inc. Compositions and methods for treating nonalcoholic fatty liver disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5935777A (en) * 1991-02-19 1999-08-10 University Of Florida Research Foundation, Inc. Entomopoxvirus expression system
US6051429A (en) * 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
BR9610058A (pt) * 1995-07-28 1999-07-27 Marie Curie Cancer Care Uso de vp22 ou uma porção ativa fragmento ou homólogo do mesmo proteína de transporte ácido nucleíco vetor de expressão célula hospedeira de mamíferos ou microbiana e processos para transportar uma proteína ou peptídeo desejado para uma população de marcaç o de células e para transportar uma molécula desejada em uma população de células
EP0880596A1 (de) * 1995-12-28 1998-12-02 Chiron Corporation Rezeptorspezifische, chimäre, virale oberflächenpolypeptide für die übertragung von viralen oder nicht-viralen partikeln in zielzellen.
US6017735A (en) * 1997-01-23 2000-01-25 Marie Curie Cancer Care Materials and methods for intracellular transport and their uses
US6034135A (en) * 1997-03-06 2000-03-07 Promega Biosciences, Inc. Dimeric cationic lipids
GB9705903D0 (en) * 1997-03-21 1997-05-07 Elliott Gillian D VP22 Proteins and uses thereof
DE69827260T2 (de) * 1997-07-24 2006-02-16 PerSeptive Biosystems, Inc., Framingham Konjugate von transportpeptiden und nukleinsäureanaloga und deren verwendung
GB9816761D0 (en) * 1998-07-31 1998-09-30 Phogen Limited Herpesvirus preparations and their uses
GB9930519D0 (en) * 1999-12-24 2000-02-16 Phogen Limited Uses of transport proteins

Also Published As

Publication number Publication date
AU3176500A (en) 2000-09-28
CA2365625A1 (en) 2000-09-14
EP1159441B8 (de) 2008-10-29
WO2000053722A2 (en) 2000-09-14
WO2000053722A3 (en) 2001-07-12
ATE408699T1 (de) 2008-10-15
JP2002537828A (ja) 2002-11-12
MXPA01009073A (es) 2002-05-06
EP1159441B1 (de) 2008-09-17
US20040171044A1 (en) 2004-09-02
AU767195B2 (en) 2003-11-06
EP1159441A2 (de) 2001-12-05

Similar Documents

Publication Publication Date Title
DE60040274D1 (de) Verabreichung von nukleinsäuren und proteinen an zellen
DE50006269D1 (de) Kombinationen zur einführung von nucleinsäuren in zellen
IL152886A0 (en) B-7 related nucleic acids and polypeptides and pharmaceutical compositions containing the same
DE69637147D1 (de) Transportproteine und deren verwendungen
DE69943068D1 (de) Transfer von mRNA unter Verwendung von polykationischen Verbindungen
ATE368054T1 (de) Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität
AU4778101A (en) Novel polypeptides, and nucleic acids encoding the same
EP2078753A3 (de) Mit der Zellproliferation zusammenhängende Polypeptide und Verwendungen dafür
ATE199377T1 (de) Protein mit cytokinaktivität, rekombinant-dns, expressionsvektor und wirtszellen zu seiner herstellung
WO1999045098A3 (en) Delivery or proteins into eukaryotic cells with recombinant yersinia
WO1999003881A3 (fr) Polypeptide chimerique comprenant le fragment b de la toxine shiga et des peptides d'interet therapeutique
ES2155821T3 (es) Toxinas quimericas mejoradas.
ES2114548T3 (es) Procedimiento y composiciones para ensayos de complementacion de enzima utilizando la region omega de beta-galactosidasa.
TR200103339T2 (tr) Geliştirilmiş çözülürlük özelliklerine sahip yeni LHRH-antagonistleri.
ITRM990803A0 (it) Peptidi stabilizzanti, polipeptidi ed anticorpi che li comprendono.
ES2157900T3 (es) Nuevos conjugados de proteinas y policationes.
TR199902575T2 (xx) Peptitler, proteinler ve nükleik asitler için stabil farmasötik uygulama formu.
TR199802376T1 (xx) Aspergıllus Phoenıces'den Oksalat Dekarboksilaz Kodlayan Gen.
ATE355302T1 (de) N-substituierte d-aminosäuren enthaltende peptide,zur prävention der beta-strang assoziation
EA200000270A1 (ru) КОМПОЗИЦИИ ДЛЯ ГЕНОТЕРАПИИ С ИСПОЛЬЗОВАНИЕМ ГЕНОВ, КОДИРУЮЩИХ СЕКРЕТИРУЕМЫЕ БЕЛКИ, ТАКИЕ КАК β-ИНТЕРФЕРОН, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
DE602004028266D1 (de) Angiogene peptide und ihre verwendungen
DE69033756D1 (de) Gene, die für MACIF Proteine kodieren, Expressionsvektoren mit diesem Genen, und Transformantenzellen mit diesem Proteinen
DE69704269D1 (de) Dendritische, lysinhaltige Polypeptide zur gezielten Arzneimittelabreichung
WO2000071566A3 (en) Novel organic anion transport proteins
ATE414771T1 (de) Galaninrezeptor, nukleinsäuren,transformierte zellen und verwendungen

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: MARIE CURIE CANCER CARE, LONDON, GB

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee